UY38431A - Formulación basada en ciclodextrina de un inhibidor de bcl-2 - Google Patents

Formulación basada en ciclodextrina de un inhibidor de bcl-2

Info

Publication number
UY38431A
UY38431A UY0001038431A UY38431A UY38431A UY 38431 A UY38431 A UY 38431A UY 0001038431 A UY0001038431 A UY 0001038431A UY 38431 A UY38431 A UY 38431A UY 38431 A UY38431 A UY 38431A
Authority
UY
Uruguay
Prior art keywords
cyclodextrin
pharmaceutical composition
relates
bcl
inhibitor
Prior art date
Application number
UY0001038431A
Other languages
English (en)
Inventor
Chanrion Maïa
Caroline Chemin
Tran Thu Thuy
Pean Jean-Manuel
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of UY38431A publication Critical patent/UY38431A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una composición farmacéutica que comprende 5-(5-cloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroisoquinolin-2(1H)-il]carbonil}fenil)-N-(5-ciano-1,2-dimetil-1H-pirrol-3-il)-N-(4-hidroxifenil)-1,2-dimetil-1H-pirrol-3-carboxamida, referida en la presente memoria como ‘Compuesto A’, o una sal farmacéuticamente aceptable de la misma, y una ciclodextrina. Más específicamente, la invención se refiere a una composición farmacéutica sólida que comprende el Compuesto A y una ciclodextrina, y una composición farmacéutica para administración parenteral preparada disolviendo esta composición farmacéutica sólida. Además, la invención se refiere al uso de dichas composiciones para el tratamiento del cáncer.
UY0001038431A 2018-10-31 2019-10-29 Formulación basada en ciclodextrina de un inhibidor de bcl-2 UY38431A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862753164P 2018-10-31 2018-10-31

Publications (1)

Publication Number Publication Date
UY38431A true UY38431A (es) 2020-05-29

Family

ID=68536777

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038431A UY38431A (es) 2018-10-31 2019-10-29 Formulación basada en ciclodextrina de un inhibidor de bcl-2

Country Status (25)

Country Link
US (1) US20210353633A1 (es)
EP (1) EP3873529A1 (es)
JP (1) JP7526175B2 (es)
KR (1) KR20210102886A (es)
CN (1) CN112912108A (es)
AR (1) AR116922A1 (es)
AU (1) AU2019373373B2 (es)
BR (1) BR112021007987A2 (es)
CL (1) CL2021001018A1 (es)
CO (1) CO2021005221A2 (es)
CR (1) CR20210210A (es)
DO (1) DOP2021000073A (es)
EA (1) EA202191144A1 (es)
GE (2) GEP20237580B (es)
IL (1) IL282688A (es)
JO (1) JOP20210079A1 (es)
MX (1) MX2021004864A (es)
NI (1) NI202100031A (es)
PE (1) PE20211738A1 (es)
PH (1) PH12021550878A1 (es)
PY (1) PY1990875A (es)
SG (1) SG11202103965TA (es)
TW (1) TWI738100B (es)
UY (1) UY38431A (es)
WO (1) WO2020089286A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3190276A1 (en) 2020-07-31 2022-02-03 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
EP4313964A1 (en) 2021-03-24 2024-02-07 Les Laboratoires Servier New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h )-carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5774796A (en) * 1995-06-13 1997-01-09 Dyer, Alison Margaret Pharmaceutical compositions containing lornoxicam and cyclod extrin
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
WO2014108918A2 (en) * 2013-01-08 2014-07-17 Mylan Laboratories Limited An injectable antifungal formulation
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018015526A1 (en) * 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
US20200054639A1 (en) * 2016-10-31 2020-02-20 Oregon Health & Science University Combinations of agents to treat hematological malignancies

Also Published As

Publication number Publication date
WO2020089286A1 (en) 2020-05-07
GEAP202315618A (en) 2023-08-10
BR112021007987A2 (pt) 2021-08-03
EA202191144A1 (ru) 2021-09-27
NI202100031A (es) 2021-08-24
PH12021550878A1 (en) 2021-10-18
MX2021004864A (es) 2021-08-11
JP2022506069A (ja) 2022-01-17
CN112912108A (zh) 2021-06-04
CA3117511A1 (en) 2020-05-07
EP3873529A1 (en) 2021-09-08
CL2021001018A1 (es) 2021-11-26
KR20210102886A (ko) 2021-08-20
AU2019373373B2 (en) 2023-09-28
PE20211738A1 (es) 2021-09-06
CO2021005221A2 (es) 2021-07-19
TWI738100B (zh) 2021-09-01
DOP2021000073A (es) 2021-11-15
TW202031295A (zh) 2020-09-01
PY1990875A (es) 2020-05-04
AU2019373373A1 (en) 2021-05-20
JP7526175B2 (ja) 2024-07-31
US20210353633A1 (en) 2021-11-18
GEP20237580B (en) 2023-12-25
SG11202103965TA (en) 2021-05-28
CR20210210A (es) 2021-05-25
IL282688A (en) 2021-06-30
JOP20210079A1 (ar) 2023-01-30
AR116922A1 (es) 2021-06-30

Similar Documents

Publication Publication Date Title
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
CL2021001018A1 (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
NZ588913A (en) Liver cancer drug
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CL2021001629A1 (es) Compuestos de halo-alilamina y uso de los mismos
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
BR112022002392A2 (pt) Formas em estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1)-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e seus usos
BR112022019864A2 (pt) Composto de oxofenilarsina deuterada e uso do mesmo
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
JP2022028975A5 (es)
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
BRPI0418743A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
AR117719A1 (es) Formulaciones orales de branaplam
GEP20227372B (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
US9907797B2 (en) Combination therapies for overcoming resistance to mitotic agents during chemotherapy
PE20252784A1 (es) Composiciones y metodos para administrar paltusotina a pacientes con insuficiencia hepatica
AR124337A1 (es) Formulaciones farmacéuticas de un profármaco fenólico agonista del trpv1

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20250911